Please assess the completion status of the following clinical trial:

Trial Title: Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of any age undergoing allogeneic or autologous HCT~* Histologic TMA diagnosis OR clinical TMA diagnosis and presenting with high risk disease features including elevated plasma sC5b-9 above laboratory normal value (≥244ng/ml) and proteinuria measured as ≥30mg/dL of protein on random urinalysis x2 or protein/creatinine ratio ≥1mg/mg or patient receiving renal replacement therapy.~* Minimum weight of ≥ 5kg.~Exclusion Criteria:~* Known hypersensitivity to any constituent of the study medication.~* Subjects with unresolved serious Neisseria meningitides infection or progressive severe infection.~* Patients with diagnosis of TTP as defined by ADAMST13 activity test \<10%.~* Patients previously treated with eculizumab or other complement blocker for TMA within the 60 days prior to first dose of study treatment.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): All patients will receive eculizumab based on their weight for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).